Logo

nucleosome diagnostics

VolitionRx Gets €5M Financing From Wallonie Entreprendre

The Nevada-based epigenetics firm will receive half the money through an unsecured loan and half through the sale of restricted common stock.

VolitionRx Signs on Diagnostic Oncology CRO for Clinical Studies of Cancer, Sepsis Tests

DXOCRO will conduct large-scale clinical utility studies of Volition's Nu.Q NETs and Nu.Q Cancer tests at multiple sites in the US.

VolitionRx Secures $1.5M Loan From Namur Invest Capital Risk

The non-dilutive funding will go toward an early-access program for Volition's Nu.Q nucleosome quantification technology in the US, EU, and UK.

Delfi Diagnostics Nets $100M in Series A Financing, Plans Multi-Cancer Screening Test

The company intends to develop its fragmentomic approach for early cancer detection both in individual tumor types and for multi-cancer screening.

VolitionRx, 4D Lifetec Partner to Combine Early Cancer Detection Assays

The companies said Tuesday that they are pursuing a clinical trial utilizing their respective liquid biopsy assays on clinical samples from lung cancer patients.